This site is optimised for modern browsers. For the best experience, please use Google Chrome, Mozilla Firefox, or Microsoft Edge.

Immunotherapy improves survival in patients with advanced bladder cancer

Immunotherapy improves survival in patients with advanced bladder cancer
An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial supported by CRN North Thames.
 
This is the first time an immune therapy has resulted in a survival advantage in this setting in bladder cancer, and will potentially benefit thousands of patients each year.
 
The results were presented in the plenary session at the American Society of Clinical Oncology, the world’s largest annual cancer meeting (ASCO20). They found that avelumab led to a 31 per cent reduction in risk of death of bladder cancer and extended median survival in advanced bladder cancer by more than seven months.
 
Approximately 550,000 new cases of bladder cancer are diagnosed each year making it the tenth most common cancer worldwide. More than 10,000 of these cases are in the UK.
 
This trial focused on the group of these patients whose cancer had spread beyond the bladder (advanced or stage 4 disease), which is difficult to treat.
 
Chemotherapy is the current initial standard of care in the treatment of these advanced cancers.
After chemotherapy is finished, patients are checked regularly because the cancer tends to return quickly. When it returns it is difficult to treat and outcomes are poor.
 
The phase III global trial, named JAVELIN Bladder 100 and funded by Pfizer and Merck KGaA Darmstadt, Germany, evaluated the efficacy of the immunotherapy drug ‘avelumab’ in patients with locally advanced or metastatic urothelial carcinoma which they received after the initial chemotherapy.
 
A total of 700 patients from over 200 sites around the world were then assigned to two treatment groups after the completion of chemotherapy – one group receiving regular checking (standard care) on its own, and the other receiving avelumab in addition to standard care.
 
Treatment with avelumab resulted in a 31 per cent reduction in risk of death and median overall survival of 21.4 months compared with 14.3 months in patients who did not receive the drug. Side effects were in line with expectations with immune therapy and 11 per cent of patients stopped avelumab due to treatment problems.
 
Study lead Tom Powles, Professor of Genitourinary Oncology at Queen Mary University of London and Director of Barts Cancer Centre, part of Barts Health NHS Trust, said: “This is the first time that an immune therapy clinical trial has shown a survival benefit for first-line therapy in metastatic bladder cancer.
 
“We saw a meaningful reduction in the risk of death and a significant overall survival benefit with avelumab, which underscores the potential for this immunotherapy to be practice-changing for patients.
 
"This highlights the potential benefits of a maintenance approach with avelumab in patients to prolong their lives following chemotherapy.”
 
Avelumab is a type of immunotherapy, known as a checkpoint inhibitor, which blocks a protein called PD-L1 on the surface of tumour cells.
 
When PD-L1 is active it helps cancers hide from the immune system. By blocking PD-L1 the immune system finds it easier to identify and kill the cancer.